Headquartered in Brussels (Belgium), UCB (www.ucb-group) is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. The company combines passion for innovation with a mission to provide therapeutic solutions for patients with severe diseases treated by specialists. Employing more than 8,400 people in over 40 countries, UCB achieved revenues of 2.5 billion euro in 2006. UCB is listed on the Euronext Brussels Exchange. UCB China’s business started in 1995. Zyrtec is widely prescribed in China to treat allergy patients. Keppra, recently launched in China in 2007, is one of the top products for UCB and is a new treatment for epilepsy that has already been successfully commercialized in several countries. The revenue for Keppra in 2006 was 761 million euro (growth of 36% as compared to 2005). Today, Keppra is the most successful new treatment for epilepsy in the USA. As UCB is to expand quickly in China and with the launch of new products in the fields of Allergy and Central Nervous System (CNS), we are inviting high-caliber individuals to join UCB China.作為**的生物制藥公司，總部設在比利時布魯塞的優時比（UCB）公司，秉承造福人類的使命，在近八十年的發展中，為**重癥疾病患者提供了若干獨具特色的藥物。優時比（UCB）公司通過采用創新的方式進行化學藥品與生物藥品的研究與開發，主要致力于中樞神經系統疾病，過敏/呼吸系統疾病、自身免疫疾病及腫瘤疾病的治療領域的研究。在重癥疾病治療領域中，優時比（UCB）公司始終處于先行者的地位。在**40多個國家擁有8,400多名員工，2006年，優時比（UCB）公司實現收入25億歐元，優時比（UCB）公司在歐洲布魯塞爾證券交易市場上市。優時比（UCB）公司在中國的業務始于1995年，總部設在上海。其專利產品仙特明和優澤被廣泛用于治療過敏疾病患者。其專利產品“開浦蘭”作為新一代抗癲癇藥，用于癲癇病的治療并成為美國成功的治療癲癇的產品之一。作為優時比（UCB）公司頂級產品之一，開浦蘭2006年在**的銷售已達到7.6億歐元（與2005年相比增長了36%）， 日前，“開浦蘭”已經在中國上市。由于優時比（UCB）公司在中國業務高速發展的需要，我們誠邀各路人才加入優時比（UCB）公司，與優時比（UCB）在中國一同成長。